June 1, 2014Open Access

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

In premenopausal women with hormone-receptor-positive early breast cancer, adjuvant treatment with exemestane plus ovarian suppression, as compared with tamoxifen plus ovarian suppression, significantly reduced recurrence. (Funded by Pfizer and others; TEXT and SOFT ClinicalTrials.gov numbers, NCT00066703 and NCT00066690, respectively.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Pagani et al. (Sun,) studied this question.

www.synapsesocial.com/papers/69d9844d0d540cafc5835fa3 — DOI: https://doi.org/10.1056/nejmoa1404037

Authors

Olivia Pagani

Meredith M. Regan

Barbara Walley

Journals

New England Journal of Medicine

Actions

Institutions

Harvard University

Inserm

Dana-Farber Cancer Institute

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion